Infectious Disease Clinical Trials

Statistical methods in infectious disease trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All infectious disease trials

903 results

• Methenamine Hippurate Versus Trimethoprim in the Prevention of Recurrent UTIs: Complete Statistical AnalysisIndependent statistical analysis of Methenamine Hippurate Versus Trimethoprim in the Prevention of Recurrent UTIs: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03077711).Phase 4Results postedn = 92NCT03077711
• Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection: Complete Statistical AnalysisIndependent statistical analysis of Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02589847).Phase 2Results postedn = 272NCT02589847
• Midodrine Use in Septic Shock: Complete Statistical AnalysisIndependent statistical analysis of Midodrine Use in Septic Shock: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03706053).Phase 3Results postedn = 10NCT03706053
• Minimal Flow Anesthesia and Infection Risk: Complete Statistical AnalysisIndependent statistical analysis of Minimal Flow Anesthesia and Infection Risk: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT07092046).Phase NAResults postedn = 140NCT07092046
• Minocycline Pharmacokinetics (ACUMIN): Complete Statistical AnalysisIndependent statistical analysis of Minocycline Pharmacokinetics (ACUMIN): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03369951).Phase 4Results postedn = 58NCT03369951
• MIS-ABC SepsisIndependent statistical analysis of Mechanistic Inflammatory Sub-study Embedded Within the Albumin vs Balanced Crystalloid Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 26NCT04963569
• MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035): Complete Statistical AnalysisIndependent statistical analysis of MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 94NCT03217136
• MK-8527 Single-Dose Trial in HIV-1 Infected Participants (MK-8527-004): Complete Statistical AnalysisIndependent statistical analysis of MK-8527 Single-Dose Trial in HIV-1 Infected Participants (MK-8527-004): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05494736).Phase 1Results postedn = 20NCT05494736
• mLab App Plus: A Randomized Controlled Trial of a Mobile Health (mHealth) Intervention: Complete Statistical AnalysisIndependent statistical analysis of mLab App Plus: A Randomized Controlled Trial of a Mobile Health (mHealth) Intervention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 40NCT06059443
• MMRIndependent statistical analysis of A Comparative Study to Assess Efficacy of Intralesional MMR Vaccine and Intralesional Vitamin D3 in Treatment of Warts: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase NAResults postedn = 66NCT04428359
• Mobile Health and COVID-19: Complete Statistical AnalysisIndependent statistical analysis of Mobile Health and COVID-19: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05074693).Phase NAResults postedn = 822NCT05074693
• Mobile Health Intervention for Active Tuberculosis: Complete Statistical AnalysisIndependent statistical analysis of Mobile Health Intervention for Active Tuberculosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03544476).Phase NAResults postedn = 42NCT03544476
• MODERNIndependent statistical analysis of Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 813NCT01345630
• MONETIndependent statistical analysis of the randomized phase 3 MONET trial of darunavir/ritonavir once daily versus darunavir/ritonavir plus two NRTIs, including its non-inferiority design, time-to-event endpoint, risk-difference estimates, confidence intervals, and statistical interpretation.Phase 3Results postedn = 256NCT00458302
• MONOIIndependent statistical analysis of the MONOI phase 3 trial of darunavir boosted with ritonavir in HIV-1 infected patients, covering the randomized design, virological success endpoint, planned statistical analysis, and interpretation.Phase 3n = 225NCT00421551
• MOVe-AHEADIndependent statistical analysis of the phase 3 MOVe-AHEAD trial of molnupiravir for prevention of Coronavirus Disease (COVID-19) in adults, including endpoint definitions, score-based confidence intervals, reported results, safety, and statistical interpretation.Phase 3Results postedn = 2,441NCT04939428
• MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial): Complete Statistical AnalysisIndependent statistical analysis of MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05780463).Phase 3Results postedn = 485NCT05780463
• MRKAd5 HIV-1 Gag Vaccine (V520) in Subjects With Chronic Hepatitis C (V520-022) (COMPLETED): Complete Statistical AnalysisIndependent statistical analysis of MRKAd5 HIV-1 Gag Vaccine (V520) in Subjects With Chronic Hepatitis C (V520-022) (COMPLETED): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1Results postedn = 17NCT00857311
• MSG-01Independent statistical analysis of Randomized Study of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in the Intensive Care Unit (ICU): primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 4Results postedn = 222NCT00520234
• MTBVACIndependent statistical analysis of Dose-Escalation Study to Evaluate the Safety and Immunogenicity of MTBVAC Vaccine in Comparison With BCG Vaccine.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 1Results postedn = 36NCT02013245
• Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination: Complete Statistical AnalysisIndependent statistical analysis of Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04722003).Phase 2Results postedn = 52NCT04722003
• Multi-Component Intervention to Improve Health Outcomes and Quality of Life Among Rural Older Adults Living With HIV: Complete Statistical AnalysisIndependent statistical analysis of Multi-Component Intervention to Improve Health Outcomes and Quality of Life Among Rural Older Adults Living With HIV: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase NAResults postedn = 61NCT04549259
• Multidisciplinary Support Program in Chronic Hepatitis C: Complete Statistical AnalysisIndependent statistical analysis of Multidisciplinary Support Program in Chronic Hepatitis C: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01850745).Phase NAResults postedn = 447NCT01850745
• MUSICIndependent statistical analysis of Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04484935).Phase 2Results postedn = 100NCT04484935
• MVA-BN-RSV Vaccine Trial: Complete Statistical AnalysisIndependent statistical analysis of MVA-BN-RSV Vaccine Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05238025).Phase 3Results postedn = 20,419NCT05238025
• Myocardial Injury and Quality of Life After COVID-19: Complete Statistical AnalysisIndependent statistical analysis of Myocardial Injury and Quality of Life After COVID-19: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04794062).Phase NAResults postedn = 119NCT04794062
• NADIAAn independent statistical analysis of the randomized phase 3 NADIA trial evaluating darunavir/ritonavir and dolutegravir-based treatment strategies in people with human immunodeficiency virus, including its factorial design, 48-week viral-load endpoint, and planned…Phase 3n = 465NCT03988452
• Nasal Physiologic Reactivity of Nonallergic Rhinitics to Cold Air Provocation: Complete Statistical AnalysisIndependent statistical analysis of Nasal Physiologic Reactivity of Nonallergic Rhinitics to Cold Air Provocation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00415493).Phase NAResults postedn = 24NCT00415493
• NavigatorIndependent statistical analysis of A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and Without Ribavirin (RBV) in Treatment-Naïve Participants With Genotype 1, 2 or 3…Phase 2Results postedn = 61NCT01458535
• Negative Beta Glucan in ICU Patients: Complete Statistical AnalysisIndependent statistical analysis of Negative Beta Glucan in ICU Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01734525).Phase 4Results postedn = 85NCT01734525
• Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04869137).Phase 2Results postedn = 26NCT04869137
• NeuroCovid Rehab and Recovery Related to COVID-19 Diagnosis: Complete Statistical AnalysisIndependent statistical analysis of NeuroCovid Rehab and Recovery Related to COVID-19 Diagnosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04638673).Phase 2Results postedn = 13NCT04638673
• NewHopeIndependent statistical analysis of Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1/2Results postedn = 151NCT01246401
• NextCOVEComplete statistical analysis of the phase 3 NextCOVE trial comparing mRNA-1283 with mRNA-1273 for prevention of COVID-19 in participants aged 12 years and older, including non-inferiority methodology, antibody endpoints, COVID-19 efficacy, safety,…Phase 3Results postedn = 13,553NCT05815498
• Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV: Complete Statistical AnalysisIndependent statistical analysis of Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 130NCT00090779
• Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 33NCT02426892
• NIXIndependent statistical analysis of the phase 3 NIX trial evaluating bedaquiline, PA-824, and linezolid in participants with drug-resistant pulmonary tuberculosis, including trial design, the bacteriologic and clinical treatment-failure endpoint, planned statistical interpretation,…Phase 3Results postedn = 109NCT02333799
• NOHARMIndependent statistical analysis of Novel Use Of Hydroxyurea in an African Region With Malaria: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01976416).Phase 3Results postedn = 208NCT01976416
• Norovirus Bivalent-Vaccine Efficacy Study: Complete Statistical AnalysisIndependent statistical analysis of Norovirus Bivalent-Vaccine Efficacy Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01609257).Phase 1/2Results postedn = 132NCT01609257
• NPWT in Patients Undergoing Surgical Procedures for Management of GI Malignancies: Complete Statistical AnalysisIndependent statistical analysis of NPWT in Patients Undergoing Surgical Procedures for Management of GI Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2/3Results postedn = 290NCT04955730
• Nutraceutical Efficacy for rUTI: Complete Statistical AnalysisIndependent statistical analysis of Nutraceutical Efficacy for rUTI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03395288).Phase 2/3Results postedn = 61NCT03395288
• OAKTREEComplete statistical analysis of the randomized phase 3 OAKTREE trial of obeldesivir in nonhospitalized participants with COVID-19, including trial design, endpoints, survival analysis, viral-load analysis, safety, statistical methodology, results, and interpretation.Phase 3Results postedn = 2,011NCT05715528
• Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice: Complete Statistical AnalysisIndependent statistical analysis of Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase NAResults postedn = 398NCT01524900
• OLAIndependent statistical analysis of Oligonucleotide Ligation Assay (OLA) Resistance Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01898754).Phase NAResults postedn = 991NCT01898754
• onceMRKIndependent statistical analysis of Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292): primary…Phase 3Results postedn = 802NCT02131233
• One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age: Complete Statistical AnalysisIndependent statistical analysis of One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response…Phase 3Results postedn = 508NCT01139021
• Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2Results postedn = 43NCT04980482
• Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa: Complete Statistical AnalysisIndependent statistical analysis of Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02904902).Phase 3Results postedn = 15NCT02904902
• Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) – Tuberculosis (TB) Co-infection: Complete Statistical AnalysisIndependent statistical analysis of Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 113NCT02178592
• Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country: Complete Statistical AnalysisIndependent statistical analysis of Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 300NCT01296360

← All therapeutic areas